Dermal Filler Side Effects and Risks: What Is Normal and What Is Not

Juvéderm's safety information calls its common side effects consistent with other facial injection procedures.

The FDA groups dermal filler risks by how often they are reported, and its tiers look like this:

• Common risks: bruising, redness, swelling, pain, tenderness, itching and rash.
• Less common risks: nodules or granulomas, infection, allergic reaction and necrosis (tissue death).
• Rare reported risks: anaphylaxis, migration of filler, permanent hard nodules, blindness, stroke and death.

Product labeling fills in the detail.

Juvéderm's safety information lists redness, swelling, pain, tenderness, firmness, lumps or bumps, bruising, discoloration and itching as the most common side effects, with dryness also reported for Volbella XC, and say most resolve within 30 days.

Trial diaries show how routine these reactions are.

In the Restylane Kysse trial for lips, 90.2% of subjects reported swelling, 87.4% tenderness and 85.8% bruising after initial treatment, and most reactions were tolerable and lasted less than 2 weeks.

Those are trial figures for one lip product, not a prediction for any one person or area.

FDA adds a caveat worth reading twice: side effects such as swelling and bruising usually appear soon after injection, and many resolve in days to weeks, but some side effects may appear weeks, months or years later.

A reaction that shows up months after treatment is one of those late-appearing side effects FDA warns about — the lumps section below covers it.

FDA's general statement covers all fillers: swelling and bruising usually appear soon after injection, and many resolve in days to weeks.

Labels and trials then get product-specific.

The Restylane Kysse label expects injection-related reactions — bruising, redness, itching, swelling, pain and tenderness — to generally resolve on their own within one week.

In the Kysse trial, most diary-reported reactions lasted less than 2 weeks, and treatment-related bruising specifically lasted less than 14 days.

Allergan's own figures differ by product and area.

In the Juvéderm Voluma XC cheek study, the most common side effects were rated moderate and generally lasted 2 to 4 weeks; for Juvéderm Volbella XC in the lips, they were mild or moderate and generally lasted 30 days or less.

Juvéderm's safety information says most of its common side effects resolve within 30 days.

So the published timelines run from one week to 30 days, depending on the product and the study behind it.

If swelling or bruising is getting worse rather than better, or has not settled on the timeline your provider described, contact the provider who treated you.

Early lumps are among the common, usually short-lived side effects.

Firmness and lumps or bumps are on Juvéderm's most-common list, and in the Restylane Kysse trial, treatment-related injection-site masses occurred in 10.3% of subjects and nodules in 5.4% — typically lasting less than 30 days, with bruising under 14 days.

Lumps that surface weeks or months later are a different thing.

FDA lists nodules and granulomas among its less common filler risks, and the published figures come from single-clinic series: delayed-onset nodules after Allergan's Vycross fillers (Volbella, Vollure and Voluma) occurred in 0.33% of 2,139 patients at one Canadian clinic, and an earlier US chart review found them in 1.0% per patient for Volbella and in none treated with Vollure or Voluma.

Every nodule in that US series resolved with steroid injection plus hyaluronidase.

These are single-clinic figures, not product-wide rates.

Filler can also move.

FDA lists migration among its rare reported risks, and a 2023 review of 53 published lip-filler complication cases found nodules were the most common complication, with migration, discoloration and herpes outbreaks linked to filler placed in the lip area.

Under the eyes, filler placed too superficially in thin skin can read as a bluish tint.

The Restylane Eyelight label warns about bluish discolouration from too-superficial injection, and a 2023 meta-analysis of hyaluronic acid filler for tear troughs found contour irregularity or lumps in 5.3% of cases and blue discoloration or a Tyndall effect in 0.9%.

Fixes depend on the material.

Juvéderm's safety information says persistent side effects may be treated with antibiotics, steroids or hyaluronidase.

Hyaluronidase breaks down hyaluronic acid only, per Cleveland Clinic, and products such as Hylenex are approved only as an adjuvant for subcutaneous fluid administration, to increase the dispersion of other injected drugs and in subcutaneous urography — so dissolving filler is an off-label use.

FDA says removal can require injections, surgery or other interventions with their own risks, and may be difficult or impossible for permanent fillers or fillers not made of hyaluronic acid; Allergan's safety information adds that the effectiveness of removal of any dermal filler has not been studied.

Material matters beyond reversal too: FDA notes that calcium hydroxylapatite filler (Radiesse) is visible on X-rays and may obscure underlying features while in the body.

FDA's single most concerning filler risk is unintentional injection into a blood vessel.

It is rare, but a vessel blocked by filler can cut off blood supply to tissue, causing tissue death (necrosis), vision problems including blindness, and stroke — and the damage may be permanent.

How rare is rare?

There is no single occlusion rate to quote: the figures that exist come from specific datasets and only make sense with their context.

In a 2021 study in JAMA Dermatology, 370 US board-certified dermatologists self-reported 1.7 million syringes of filler.

Vascular occlusion occurred about once per 6,410 one-milliliter syringes injected with a needle and once per 40,882 with a cannula; the risk never exceeded 1 per 5,000 syringes for any filler type; 85% of occlusions had no long-term sequelae; and nasolabial folds and lips were the sites most likely to be occluded.

A single Japanese clinic chain's retrospective review of 290,307 hyaluronic acid injections in 209,083 patients (October 2020 to April 2024) found 12 serious complications — 10 vascular obstructions and 2 infections — an incidence of 0.0041%, and 8 of the 10 vascular events followed forehead injection.

Vision loss after filler is documented case by case, and those published cases are counts, not incidence rates:

What vascular compromise looks like in the clinical literature: skin blanching, a lace-like purple pattern called livedo reticularis, slow capillary refill and dusky blue-red discoloration, followed a few days later by blisters and tissue slough.

The true incidence is unknown, the review notes, because of under-reporting.

In post-marketing surveillance for Restylane Kysse, the most commonly reported serious adverse events — spontaneous reports, not incidence rates — were ischemia or necrosis, swelling, angioedema, infection and nodules, with the ischemia and necrosis cases treated with measures including hyaluronidase.

Our page on vascular occlusion warning signs covers this emergency in detail: what injectors are told to do, and what treatment can and cannot reverse.

FDA has approved dermal fillers for adults 22 and older, with each product's label setting the exact age — and it says safety is unknown below that line, during pregnancy, and while breastfeeding.

FDA also names people prone to keloid or hypertrophic scarring as a group where filler safety is unknown, and says treatment should be delayed if the skin is inflamed or infected.

The Restylane Kysse label adds detail: people with abnormal wound healing or dark skin (Fitzpatrick types IV to VI) may be more prone to hypertrophic scarring and keloid formation, and inflammatory pigment changes and scarring may occur.

Disclosures FDA asks patients to make before treatment: bleeding disorders, severe allergies or anaphylaxis, and allergies to lidocaine, collagen, eggs, animal products or bacteria.

Juvéderm's contraindications overlap that list: no treatment with a history of multiple severe allergies or anaphylaxis, allergy to lidocaine or to the gram-positive bacterial proteins used in the products, or a prior allergic reaction to a hyaluronic acid filler.

Start with the person holding the syringe.

FDA advises choosing a licensed health care provider with dermatology or plastic-surgery experience who is trained in filler injection, and says filler injection should be considered a medical procedure, not a cosmetic treatment.

FDA's instructions to injectors double as questions to ask before you book: injectors are told to know the signs of intravascular injection, to keep an updated plan for treating it — on-site treatment and/or immediate referral — and to stop injecting at signs such as skin blanching, vision change, stroke signs or unusual pain.

Two don'ts come straight from the FDA: do not inject yourself with dermal filler, and do not buy filler online, because products sold that way could be counterfeit or not approved for use in the US.

Needle-free devices such as "hyaluron pens" are not approved for injecting dermal fillers, and no filler is approved for over-the-counter use.

Aftercare is product-specific, so follow the sheet your own provider gives you.

Juvéderm's labeling, for example, advises avoiding makeup for 12 hours after treatment and minimizing strenuous exercise, extensive sun or heat exposure, and alcohol in the first 24 hours, because these may cause temporary redness, swelling and/or itching.

What goes in matters too.

Dermal fillers are medical device implants that FDA approves product by product for specific uses, and FDA notes that the safety of fillers combined with neuromodulators such as Botox, or of repeated use over a long period, has not been evaluated in controlled clinical studies.

Our dermal fillers guide covers the products and the areas each is approved for.